Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry.

BACKGROUND: the admission and death causes of SLE patients might have changed over the last years. METHODS: Analysis of the Spanish National Hospital Discharge database. All individuals admitted with SLE, according to ICD-9, were selected. The following five admission categories were considered: SLE, cardiovascular disease (CVD), neoplasm, infection, and venous-thromboembolic disease (VTED), along four periods of time (1997-2000, 2001-2005, 2006-2010, and 2011-2015). RESULTS: The admissions (99,859) from 43.432 patients with SLE were included. The absolute number of admissions increased from 15,807 in 1997-2000 to 31,977 in 2011-2015. SLE decreased as a cause of admission (from 47.1% to 20.8%, p < 0.001), while other categories increased over the time, as follows: 5% to 8.6% for CVD, 8.2% to 13% for infection, and 1.4% to 5.5% for neoplasm (p < 0.001 for all). The admission mortality rate rose from 2.22% to 3.06% (p < 0.001) and the causes of death evolved in parallel with the admission categories. A significant trend to older age was observed over time in the overall population and deceased patients (p < 0.001). CONCLUSIONS: Better control of SLE over the past two decades has led to a decrease in early admissions, and disease chronification. As a counterpart, CVD, infections, and neoplasm have become the main causes of admissions and mortality.

[Safety and tolerance of beta-blocker treatment in elderly patients with heart failure. BETANIC study]. / Seguridad y tolerancia del tratamiento con bloqueadores beta en el paciente anciano con insuficiencia cardíaca. Estudio BETANIC.

BACKGROUND AND OBJECTIVE: Prescription of beta-blockers (BB) in elderly patients with heart failure (HF) is very low, and it probably owes to an excessive concern about the risk of adverse reactions. The objective of our study was to determine the safety and tolerance of BB in elderly patients with HF in an Internal Medicine clinical practice. MATERIAL AND METHODS: This observational prospective study of clinical practice included 119 patients older than 70 years with HF evaluated in 10 Internal Medicine services. Patients must have started treatment with BB (carvedilol or bisoprolol) within the last month. After 6 months of follow-up, the percentage of patients on BB, the dose achieved and the causes of withdrawal were analyzed. RESULTS: At the end of the study, 100 patients (84%) were on BB treatment. There were 3 deaths (2.5%), none related to BB use, and 6 losses to follow-up (5%). The treatment was stopped in 10 patients (8.4%). Maximum dose was achieved in 38.7% of the patients. Adverse reactions responsible for treatment withdrawal were: symptomatic hypotension (3 cases; 2.5%); asymptomatic hypotension (1 case; 0.8%); heart failure (2 cases; 1.7%); bradycardia (2 cases; 1.7%); bronchospasm (1 case; 0.8%); and unknown cause (1 case; 0.8%). CONCLUSIONS: BB are excellently tolerated in elderly patients with HF treated in an Internal Medicine setting.

[Acute myocardial ischemia and ventricular thrombus associated with pheochromocytoma]. / Isquemia miocárdica aguda y trombosis ventricular asociadas a feocromocitoma.

We describe a patient with a suprarenal pheochromocytoma that had a complex course with electrocardiographic findings characteristic of diffuse myocardial damage, normal findings on coronary angiography, and left intraventricular thrombus complicated by embolic stroke.

Prognostic factors in Hodgkin's disease.

Hodgkin's disease (HD) is a curable tumoral disease. However, there are groups of patients who suffer relapse and the identification of prognostic factors and the adaptation of treatments to individual risk is one the lines of investigation in this disease. A study was performed on 526 patients diagnosed of HD in our hospital between January 1967 and September 2001. An analysis was made of the most important variables in terms of both disease-free and overall survival. Overall survival in this series of patients was 94% at 2 years, 86% at 5 years, 76% at 10 years and 72% at 15 years. Median survival was 249 months. Factors influencing poor prognosis in the overall survival were: male gender (P < 0.0001), lymphocyte depletion (P < 0.0001), stages III and IV (P < 0.0001), B symptoms (P < 0.0001), spleen involvement at diagnosis (P = 0.003), no complete remission after first line treatment (P < 0.0001), and more than 30 years-of-age (P < 0.0001). Disease free survival was 83% at 2 years and 68% at 5 years although without reaching the mean follow-up. The disease free survival study revealed the following risk factors: male gender (P = 0.02), lymphocyte depletion (P < 0.0001), stages III and IV (P < 0.001), B symptoms (P < 0.001), extranodal or splenic involvement (P < 0.05), and no complete remission after first line treatment (P < 0.0001). The result of treatment optimization is that some factors that were considered to indicate a poor prognosis have disappeared, and that others which are useful have appeared and allow us to establish groups with differing risks of relapse and who could be candidates for differentiated treatments.

Importance of Bnp changes during the follow-up in elderly outpatients with heart failure.

BACKGROUND: The aim of the present study was to analyze whether absolute BNP and relative BNP change values during follow-up of elderly patients with chronic HF could predict the development of acute decompensated episodes. METHODS AND RESULTS: A total population of 108 elderly outpatients with the diagnosis of HF was retrospectively reviewed. Available BNP levels after at least one stable visit and one acute decompensated episode were required. Follow-up period was 12 months (343 visits, 42.6% decompensated HF episodes). Relative BNP changes were analyzed: "CC period" (patients who remained stable) and "CD period" (patient who suffered from a decompensated HF episode). Changes in BNP levels were significantly higher in CD than in CC periods (mean and median differences 138% and 85%, vs 16% and 0%, respectively; p<0.001). The clinical model (AUC=0.83) had a sensitivity of 67.06%, and a specificity of 80.36%. Relative BNP change (29%) showed by itself, a similar AUC (0.83) and specificity (79%) and an improved sensitivity (0.80) than the clinical model. When relative BNP change was introduced at the clinical model, a similar specificity was obtained and the diagnostic accuracy, AUC (0.89 vs 0.83, p=0.01) and sensitivity were improved. Absolute BNP changes showed worse AUC than that derived from relative BNP changes or clinical assessment. CONCLUSIONS: Percent BNP change values during the follow-up showed better results than absolute BNP values and improved the clinical assessment for diagnostic of decompensated HF episodes in elderly outpatients.

Heart failure with preserved and reduced ejection fraction: different phenotypes in old-elderly patients?

BACKGROUND: Patients with heart failure with preserved ejection fraction (HFPEF) represent an important group of patients presenting in clinical practice. However, whether it is an earlier stage of heart failure with reduced ejection fraction (HFREF) remains uncertain. We evaluated the potential progression of HFPEF to HFREF. METHODS AND RESULTS: We evaluated retrospectively 178 patients (mean age 80.5±5.8 years; 75.3% females) with heart failure with preserved ejection fraction from a specialized Internal Medicine unit, offering an integrated usual care. Diagnosis of heart failure with preserved ejection fraction was made according to European guidelines. The main objective was to evaluate the progression to systolic dysfunction, defined by left ventricular ejection fraction less than 45%. Mean baseline left ventricular ejection fraction was 64.6±7.2. After a mean follow-up of 24-months, mean baseline ejection fraction was 67.1±9.3%. Only five patients (2.8%) progressed to HFREF. Brain natriuretic peptide values were significantly higher in those patients who progressed. CONCLUSIONS: These results strongly suggest that heart failure with preserved and reduced ejection fraction could be distinct pathophysiological entities, at least in elderly patients.

Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.

A large number of prognostic factors are available to help predict the course of the disease for patients with B-cell chronic lymphocytic leukemia (B-CLL). However, it is not clear the involvement of these well established prognostic factors in the clinical response of the patients with B-CLL to the chemotherapy. The possible association of the patient clinical-biological characteristics and the in vitro response to chemotherapic agents may serve to provide powerful predictive information to identify optimum treatment for patients. An apoptosis induction assay displays the patient in vitro responses to chemotherapy and the possible association with their clinical-biological characteristics. In this study, patients showed a significant better in vitro response to drugs when they were in the initial stages of the disease or with low beta(2) microglobulin serum level. Response to purine analogues was significantly higher in patients with long lymphocyte doubling time (LDT), few cells expressing CD38, normal karyotype or no p53 deletion, whereas there was no correspondence with ZAP-70 expression. Furthermore, a good correlation was shown between in vitro apoptosis induction assay and the patient clinical response to purine analogues. In conclusion, association between in vitro drug sensitivity and some of the markers considered as prognostic factors could help to develop personalised therapeutic regimens for patients with B-CLL.

Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease.

BACKGROUND: Carotid intima-media thickness (CIMT) is a surrogate marker of cardiovascular morbility. Hyperhomocysteinemia, which is an independent cardiovascular risk factor, is associated with low folate levels. The aim of this study was to evaluate the effect of folic acid treatment on the evolution of CIMT in patients with coronary disease and homocysteinemia > or =9 micromol/l. METHODS: In 137 consecutive patients with coronary disease treated with statins and normal vitamin B12 values, a randomized treatment with open-label folic acid 2.5 mg/day (group A) or not (group B) was performed during 3 years. CIMT was evaluated by two-dimensional ultrasonography baseline and at the final of the study. RESULTS: Clinical, biochemical parameters and CIMT were similar in both groups of patients. Homocysteine levels decreased (12.4+/-3.4 vs. 10.3+/-2.4 micromol/l; p<0.001) in group A, but not in group B. CIMT did not change neither in group A (0.71+/-0.23 vs. 0.69+/-0.20 mm; p=0.34) nor in group B (0.74+/-0.23 vs. 0.72+/-0.29 mm; p=0.39). In 12 patients of group A with methylenetetrahydrofolate reductase (MTHFR) 677TT mutation a decrease of CIMT was found (0.83+/-0.35 vs. 0.72+/-0.27 mm; p=0.02), but a multiple linear regression only showed a trend to the association between CIMT changes and MTHFR 677TT (p=0.051), probably due to the small number of patients with this mutation. CONCLUSIONS: Long-time treatment with folic acid in patients with coronary disease and normal values of vitamin B12 decreases homocysteine levels. A CIMT decrease is observed in treated patients with MTHFR 677TT mutation.

Respuesta: Bloqueadores beta en el paciente anciano con insuficiencia cardiaca aguda en los servicios de urgencias / Reply: Beta-blocker treatment in elderly patients with acute heart failure in the emergency departments

No disponible

Insuficiencia cardíaca y enfermedad pulmonar obstructiva crónica: un enfermo con 2 enfermedades / Heart failure and COPD, two diseases in one patient

No disponible

No disponible

Seguridad y tolerancia del tratamiento con bloqueadores beta en el paciente anciano con insuficiencia cardíaca. Estudio BETANIC / Safety and tolerance of beta-blocker treatment in elderly patients with heart failure. BETANIC study

Fundamentos y objetivo: La prescripción de tratamiento con bloqueadores beta (BB) en pacientes ancianos con insuficiencia cardíaca (IC) es muy baja y está condicionada en gran medida por el temor a sus efectos secundarios. El objetivo de nuestro estudio ha sido determinar la seguridad y la tolerancia de los BB en pacientes ancianos con IC tratados en servicios de medicina interna. Material y métodos: Es un estudio observacional prospectivo, en condiciones de actuación según la práctica clínica habitual, en el que se incluyó a 119 pacientes mayores de 70 años con IC, atendidos en 10 servicios de medicina interna, que iniciaron tratamiento con un fármaco BB (carvedilol o bisoprolol) en el último mes. A los 6 meses de seguimiento se analizó el porcentaje de pacientes que continuaban en tratamiento BB, la dosis alcanzada y las causas de retirada de la medicación. Resultados: Al final del estudio, 100 pacientes (84%) continuaban bajo tratamiento con BB y 10 pacientes lo habían suspendido (8,4%). Se produjeron 3 muertes (2,5%), ninguna atribuida al tratamiento BB, y 6 pérdidas (5%). En total, el 38,7% de los pacientes alcanzó la dosis máxima. Los efectos adversos que motivaron la suspensión del tratamiento fueron hipotensión sintomática (3 casos [2,5%]), hipotensión asintomática (un caso [0,8%]), IC (2 casos [1,7%]), bradicardia (2 casos [1,7%]), broncoespasmo (un caso [0,8%]) y causa desconocida (un caso [0,8%]).Conclusiones: La seguridad y la tolerancia del uso de BB en los pacientes ancianos con IC tratados en la práctica clínica del internista son excelentes (AU)

Background and objetive: Prescription of beta-blockers (BB) in elderly patients with heart failure (HF) is very low, and it probably owes to an excessive concern about the risk of adverse reactions. The objective of our study was to determine the safety and tolerance of BB in elderly patients with HF in an Internal Medicine clinical practice. Material and methods: This observational prospective study of clinical practice included 119 patients older than 70 years with HF evaluated in 10 Internal Medicine services. Patients must have started treatment with BB (carvedilol or bisoprolol) within the last month. After 6 months of follow-up, the percentage of patients on BB, the dose achieved and the causes of withdrawal were analyzed.Results: At the end of the study, 100 patients (84%) were on BB treatment. There were 3 deaths (2.5%), none related to BB use, and 6 losses to follow-up (5%). The treatment was stopped in 10 patients (8.4%). Maximum dose was achieved in 38.7% of the patients. Adverse reactions responsible for treatment withdrawal were: symptomatic hypotension (3 cases; 2.5%); asymptomatic hypotension (1 case; 0.8%); heart failure (2 cases; 1.7%); bradycardia (2 cases; 1.7%); bronchospasm (1 case; 0.8%); and unknown cause (1 case; 0.8%).Conclusions: BB are excellently tolerated in elderly patients with HF treated in an Internal Medicine setting (AU)

Isquemia miocárdica aguda y trombosis ventricular asociadas a feocromocitoma / Acute myocardial ischemia and ventricular thrombus associated with pheochromocytoma

Comunicamos el caso de un paciente con un feocromocitoma suprarrenal que cursó con una evolución clínica compleja, alteraciones electrocardiográficas propias de afección miocárdica difusa, con coronariografía normal y un trombo intraventricular izquierdo complicado con un ictus embólico (AU)

We describe a patient with a suprarenal pheochromocytoma that had a complex course with electrocardiographic findings characteristic of diffuse myocardial damage, normal findings on coronary angiography, and left intraventricular thrombus complicated by embolic stroke (AU)

Linfoma de Hodgkin asociado a síndrome de Sjögren primario / Hodgkin lymphoma associated with primary Sjögren's syndrome

No disponible

Micofenolato de mofetil en eltratamiento de la nefropatía lúpicaresistente a ciclofosfamida / Mycophenolate mofetil for lupus nephritis refractory to cyclophosphamide

No disponible

Endocarditis por coxiella burnetii: evolución a largo plazo de 20 pacientes / Coxiella burnetii endocarditis: Long term follow up of 20 patients

Introducción y objetivos. Coxiella burnetii es una causa cada vez más frecuente de endocarditis infecciosa de evolución subaguda asociada a una elevada morbimortalidad. Nuestro objetivo fue analizar, en una serie de 20 pacientes, la evolución clínica, serológica y terapéutica a largo plazo. Métodos. Se estudiaron retrospectivamente 20 pacientes ingresados (13 varones y 7 mujeres con una edad media de 42 ñ 10 años) entre 1982 y 1996, que cumplían criterios de Duke modificados por Raoult para endocarditis por fiebre Q. Resultados. La endocarditis asentó sobre prótesis valvular en 14 pacientes y sobre válvula nativa en 6. Todos excepto uno recibieron tratamiento antibiótico, presentando la doxiciclina en monoterapia peor resultado que combinada con otros fármacos. Fueron sometidos a recambio valvular 15 pacientes, siendo la causa más frecuente la disfunción protésica. La mortalidad global fue del 40 por ciento (8 pacientes). Actualmente, todos los pacientes mantienen valores de anticuerpos antifase I elevados tras un seguimiento entre 19 y 156 meses (media de 74 ñ 47 meses). En 5 pacientes se suspendió el tratamiento antibiótico, dada la negatividad microbiológica valvular, permaneciendo asintomáticos tras 15-65 meses (32 ñ 30) de seguimiento. Conclusiones. La endocarditis por fiebre Q se asocia a un alto índice de complicaciones severas que requieren cirugía de sustitución valvular. Todos los pacientes mantienen títulos serológicos elevados de forma crónica, sin otros datos de infección activa, lo que plantea la posibilidad de retirar el tratamiento en algún enfermo con negatividad valvular microbiológica y cuestiona el valor de la persistencia de una serología anormal como monitorización del tratamiento (AU)